A CHINESE biopharmaceutical firm is eyeing to invest in vaccine clinical trial projects and vaccines manufacturing in the Philippines, according to the Board of Investments (BoI).
In a statement on Tuesday, BoI said it met with Yisheng Biopharma Co., Ltd. officials on May 11 to discuss the company’s plans to pursue investment interests in clinical trials and for the co-development/manufacturing and marketing of vaccines with a local company.
“Yisheng Biopharma is planning for its second visit to the country to conduct face-to-face meetings and site visits on potential manufacturing sites/facilities with possible local partners, and work on the preparations for the clinical trials of its vaccines,” the BoI said.
The company already has an ongoing engagement with a known local pharmaceutical company and will be meeting with other local firms for possible partnerships on the commercialization of its vaccines, it added.
Yisheng is a company that has operations in China, United States, and Singapore. It is engaged in discovering, developing and commercializing bio therapeutics for cancers and infectious diseases using its novel PIKA immunomodulation technology. — Revin Mikhael D. Ochave
